(Bloomberg) -- Pfizer Inc. and BioNTech SE said they plan to file on Friday for an emergency use authorization that could allow their Covid-19 vaccine to be used in the U.S. next month.
The U.S. drugmaker and its German partner said earlier this week that a final analysis of clinical trial data showed the shot was 95% effective at preventing the disease. The filing with the Food and Drug Administration could permit the vaccine to be administered to high-risk populations in the U.S. by the middle to the end of December, the companies said in a statement.
©2020 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
